Caimiao Wei

机构：Pfizer (United States)

发表论文 104 篇 · 总被引 5976 次 · h-index 37

代表论文

• Long-Term Prognostic Risk After Neoadjuvant Chemotherapy Associated With Residual Cancer Burden and Breast Cancer Subtype (2017 · Journal of Clinical Oncology · 被引 744)
• Avelumab alone or in combination with chemotherapy versus chemotherapy alone in platinum-resistant or platinum-refractory ovarian cancer (JAVELIN Ovarian 200): an open-label, three-arm, randomised, phase 3 study (2021 · The Lancet Oncology · 被引 427)
• Impact of a Biomarker-Based Strategy on Oncology Drug Development: A Meta-analysis of Clinical Trials Leading to FDA Approval (2015 · JNCI Journal of the National Cancer Institute · 被引 189)
• The BATTLE-2 Study: A Biomarker-Integrated Targeted Therapy Study in Previously Treated Patients With Advanced Non–Small-Cell Lung Cancer (2016 · Journal of Clinical Oncology · 被引 185)
• Phase I/II study of the hypoxia-activated prodrug PR104 in refractory/relapsed acute myeloid leukemia and acute lymphoblastic leukemia (2015 · Haematologica · 被引 125)
• Sasanlimab plus BCG in BCG-naive, high-risk non-muscle invasive bladder cancer: the randomized phase 3 CREST trial (2025 · Nature Medicine · 被引 97)